Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 230,300 shares of the biotechnology company’s stock after selling 10,200 shares during the period. Canada Pension Plan Investment Board owned 0.24% of Sarepta Therapeutics worth $36,387,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Capital International Investors raised its position in shares of Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after buying an additional 2,917,797 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Norges Bank acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $80,697,000. Bank of Nova Scotia purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at about $50,990,000. Finally, Avoro Capital Advisors LLC raised its holdings in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Robert W. Baird lifted their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $152.00 price objective on shares of Sarepta Therapeutics in a research note on Friday. Finally, Citigroup decreased their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.39.

Sarepta Therapeutics Trading Up 0.1 %

NASDAQ:SRPT opened at $127.21 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a fifty day simple moving average of $137.26 and a 200-day simple moving average of $132.66. The company has a market capitalization of $12.02 billion, a PE ratio of 1,156.45 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.